Hemab

Hemab

Private
Copenhagen, Capital Region of DenmarkHealthcare & Life Scienceshttps://www.hemab.com

Last Round

ipo

4/10/2026

Total Funding Raised

$507M

Momentum Score

25 /100

Company Overview

Hemab Therapeutics is a biotechnology company that develops prophylactic therapeutics aimed at treating bleeding and thrombosis disorders by enhancing the body's natural clotting mechanisms to prevent life-threatening complications.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

bleeding disordersbispecific antibodyantibody therapeuticsrare bleeding disordersprophylactic therapeuticsclinical stage biotechGlanzmann Thrombastheniabiologicsvon Willebrand Diseasehematologyorphan diseasesFactor VII Deficiencydrug developmentsubcutaneous administrationthrombotic disordersmonoclonal antibody

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Hemab Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Hemab Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
ipo4/10/2026
Series C10/27/2025
Series C10/27/2023
Series B2/21/2023
Series A7/22/2021
Seed
12/14/2020

Key People

Founding team and executive leadership

Benny Sorensen

Chief Executive Officer

Executive Team

Mads Behrndt

Chief Financial Officer

Executive Team

Hemab Investors

Notable investors and investment history

InvestorRounds
Maj Invest Equity FundSeries C
Jefferiesipo
Access IndustriesSeries B
Evercore ISIipo
RA Capital ManagementSeries C, Series B, Series A
Avoro VenturesSeries C, Series B
Avoro CapitalSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 10, 2026

    $100M raised in IPO round.

  • Jan 16, 2026

    Developing gene therapies as part of its biologic product portfolio.

Hemab Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Hemab Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Hemab's valuation, stock price, and market status.

Firmographic Details

HeadquartersCopenhagen, Capital Region of Denmark
Employee Range79
Year Founded2019
Last Funding4/10/2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







DisclaimerAll investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.